Biomarkers for the early diagnosis of Alzheimer's disease

[1]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[2]  Kazuhiko Yanai,et al.  2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.

[3]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[4]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[5]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[6]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[7]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[8]  Nick C Fox,et al.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.

[9]  Henry Rusinek,et al.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. , 2003, Radiology.

[10]  Mary Ann Moran,et al.  Synthesis and Evaluation , 1986 .

[11]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[13]  Gwenn S. Smith,et al.  EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.

[14]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  J. Baron,et al.  Mild cognitive impairment , 2003, Neurology.

[16]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[17]  P. Rossini,et al.  ‘Free’ copper in serum of Alzheimer’s disease patients correlates with markers of liver function , 2007, Journal of Neural Transmission.

[18]  Alan A. Wilson,et al.  11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. , 2003, Nuclear medicine and biology.

[19]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[20]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[21]  D. Davies,et al.  MYOCARDIAL DISORDERS IN THE ELDERLY. , 1963, Lancet.

[22]  P. Rossini,et al.  Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer’s disease patients , 2008, BioMetals.

[23]  J. Trojanowski,et al.  IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques , 2002, Brain Research.

[24]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[25]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.